Current challenges and future perspectives of pharmacological testing using new approach methodologies
The mission of regulatory science is to promote human longevity by providing safer and more effective drugs and ensuring human health. At present, various in vitro and in vivo evaluation methods are used for drug development, and no major problems have been observed. However, there is still room for improvement in terms of risk prediction in humans. Thus, new approaches and methodologies (NAMs) have recently been developed to predict adverse events in humans more accurately. Based on the animal alternative methods and the current COVID-19 pandemic, in vitro methods, such as human iPS cells, and computational approach are accelerated to improve the efficiency of drug development, ensure the patients' safety and speed up the review process. In this review, we would like to summarize the current status and future perspectives of pharmacological assay system using NAM in drug development.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:156 |
|---|---|
| Enthalten in: |
Nihon yakurigaku zasshi. Folia pharmacologica Japonica - 156(2021), 4 vom: 10., Seite 208-213 |
| Sprache: |
Japanisch |
|---|
| Beteiligte Personen: |
Tsuji, Kayoko [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 02.07.2021 Date Revised 02.07.2021 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1254/fpj.21020 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM327405058 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM327405058 | ||
| 003 | DE-627 | ||
| 005 | 20231225200720.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||jpn c | ||
| 024 | 7 | |a 10.1254/fpj.21020 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1091.xml |
| 035 | |a (DE-627)NLM327405058 | ||
| 035 | |a (NLM)34193697 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a jpn | ||
| 100 | 1 | |a Tsuji, Kayoko |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Current challenges and future perspectives of pharmacological testing using new approach methodologies |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 02.07.2021 | ||
| 500 | |a Date Revised 02.07.2021 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a The mission of regulatory science is to promote human longevity by providing safer and more effective drugs and ensuring human health. At present, various in vitro and in vivo evaluation methods are used for drug development, and no major problems have been observed. However, there is still room for improvement in terms of risk prediction in humans. Thus, new approaches and methodologies (NAMs) have recently been developed to predict adverse events in humans more accurately. Based on the animal alternative methods and the current COVID-19 pandemic, in vitro methods, such as human iPS cells, and computational approach are accelerated to improve the efficiency of drug development, ensure the patients' safety and speed up the review process. In this review, we would like to summarize the current status and future perspectives of pharmacological assay system using NAM in drug development | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 700 | 1 | |a Satsuka, Ayano |e verfasserin |4 aut | |
| 700 | 1 | |a Kanda, Yasunari |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Nihon yakurigaku zasshi. Folia pharmacologica Japonica |d 1961 |g 156(2021), 4 vom: 10., Seite 208-213 |w (DE-627)NLM000003638 |x 0015-5691 |7 nnns |
| 773 | 1 | 8 | |g volume:156 |g year:2021 |g number:4 |g day:10 |g pages:208-213 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1254/fpj.21020 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 156 |j 2021 |e 4 |b 10 |h 208-213 | ||